Latest Commercialization Strategy News

Biome Australia has taken a significant step in its innovation journey by filing a patent for its next generation probiotic strain BMB18, with a clinical trial set to begin in Q4 FY26 in partnership with La Trobe University.

Imricor Medical Systems updates its SEC Form 10 with minor SEC-driven revisions as it pushes forward with FDA clearances and clinical trials, reporting a $25.3 million net loss in 2025 amid early-stage commercialisation.

Rimfire Pacific Mining has confirmed significant gold and antimony mineralisation at its Windy Ridge prospect through resampling of diamond drill core dating back 40-50 years. The findings highlight a 600-metre mineralised corridor open at depth and near surface within the Broken Hill Base Metal Project.

Mount Hope Mining (ASX:MHM) has completed Phases 1 and 2 drilling at its Mt Solitary gold project in NSW’s Cobar Basin, delivering high-grade intercepts including visible gold up to 52.5 g/t and defining an exploration target of 1.3-1.9 million tonnes at 1.0-1.35 g/t Au.

Minrex Resources appoints Max Piirto as CEO to spearhead exploration and development across its newly acquired Serbian gold and copper assets following the Electrum merger.

Orthocell has swiftly converted regulatory approval into clinical use with the first Remplir™ surgery completed in a US Department of Defense hospital, marking a key step in its US commercial expansion.

Orthocell has secured approval for its Remplir™ nerve repair device to be used across 221 U.S. military and veterans hospitals, marking a major step in its U.S. commercial expansion. The approval follows clinical validation in conflict zones, positioning Orthocell to deepen penetration into defence healthcare.

Imricor Medical Systems has submitted its NorthStar Mapping System for FDA pediatric label expansion, aiming to accelerate adoption in over 250 US children’s hospitals and broaden its commercial footprint.

Memphasys Limited (ASX: MEM) announced an investor webinar and released an updated presentation detailing its transition from early-stage commercialisation to scaling global revenues, highlighting multi-market sales, recurring cartridge revenue, and regulatory progress.

Papyrus Australia has commissioned its Adelaide Rapid Prototyping & R&D Facility, marking a key step in validating its pulp technology and progressing towards commercial production. The company also released its interim financials and reported stable cash flow supporting ongoing operations.

Lumos Diagnostics has secured a pivotal US FDA CLIA waiver for its FebriDx® test, vastly expanding its market reach and triggering milestone payments that bolster its US commercial rollout.

RLF AgTech has raised $4.5 million through an institutional placement to accelerate its commercial rollout and meet rising demand amid global fertiliser shortages.